Otsuka Pharmaceutical
Phase III2 active candidates
shared compound: Psilocybinsame indication: Major Depressive Disorder (MDD)2 shared regulatorssimilar active pipeline size
Back to StakeholdersProgramme tracker View landscape
AcquiredLead program: Phase II
Categories
1 domain / 2 areas / 1 specialization
Mindset PharmaCSE: MSET
Data updated
2 Drug Candidates
Canadian drug discovery company focused on next-generation psilocybin and DMT analogues, acquired by Otsuka Pharmaceutical in October 2023 for approximately C$80 million. Lead compound MSP-1014, a novel psilocin prodrug, received MHRA approval for a Phase 2 clinical trial in the UK for major depressive disorder.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 2
- Active programmes
- 2
- Lead stage
- Phase II
- Forecast coverage
- 2 of 2
All tracked candidates active
All tracked programmes active
Multiple active stages
2 active programmes with forecast fields
Latest sourced update
ClinicalTrials.gov NCT07329621 - MSP-2020 5-HT2A PET Binding Study
Jun 12, 2026 - clinical-trial-registry - ClinicalTrials.gov - MSP-2020
Next known catalyst
Phase II topline
Timing not specified - MSP-1014 / MSP-1014 Phase 2 Programme (MDD) — acquired by Otsuka - Confidence: 50%
5 sources0 pipeline-linked trials0 pipeline-linked papers1 Phase II1 Phase I
Development Programmes
2MSP-1014
PsilocybinPhase II
Major depressive disorder
Programme Tracker
Major Depressive Disorder (MDD)
Primary: UK (MHRA)
Phase IIActive
Forecast
Phase II topline
MHRA-approved Phase 2 trial (NCT05624268) for MDD with ACT psychotherapy; may be deprioritized in favor of MSP-2020
Milestones
Licensing deal
CompletedActual: Sep 1, 2023
Otsuka Pharmaceutical announces acquisition of Mindset Pharma for CAD ~$80M ($0.75/share, ~50% premium)
Why it matters: One of the first Big Pharma acquisitions in the psychedelic therapeutics space. Otsuka (parent of Lundbeck partner and antipsychotics leader) gaining a psilocin prodrug and next-gen tryptamine platform signals serious pharmaceutical industry commitment to psychedelic medicine.
Company milestone
CompletedActual: Jan 1, 2024
Otsuka formally completes acquisition of Mindset Pharma; company fully absorbed
Why it matters: Mindset Pharma ceases to exist as an independent entity. All IP, including MSP-1014, MSP-2020, MSP-2003, and DMT-inspired compounds, now owned by Otsuka.
Recorded Events
Jan 1, 2024: Company milestone
Sep 1, 2023: Licensing deal
Evidence Links
Mindset Receives Approval for Phase II Trial Evaluating MSP-1014 in MDD
Press release - BioSpace / Newsfile - Jun 22, 2023 - Verified
Mindset announced MHRA and Research Ethics Committee approval to initiate a Phase II MSP-1014 study in major depressive disorder.
Otsuka Pharmaceutical to Acquire Mindset Pharma
Press release - Newsfile / Otsuka and Mindset - Aug 31, 2023 - Verified
Otsuka announced acquisition of Mindset for approximately CAD $80M following the companies’ psychedelic-medicine partnership.
MSP-2020
Phase I
Major depressive disorder
Programme Tracker
Major Depressive Disorder (MDD)
Primary: US (FDA)
Phase IActive
MSP-2020 is listed in Otsuka's Mar. 31, 2026 pipeline as an oral Phase I psychiatry/neurology programme. A recruiting Phase 1 PET/brain-imaging study, NCT07329621, began in January 2026.
Milestones
phase-1-initiated
In progressMSP-2020 listed as Phase 1 on Otsuka pipeline (January 2026)
Why it matters: Now the lead Mindset-sourced asset on Otsuka's pipeline, superseding MSP-1014. Otsuka's March 2026 acquisition of Transcend Therapeutics ($1.225B, TSND-201 MDMA analog for PTSD) shows massive commitment to neuroplastogens — MSP-2020 fits into this expanding portfolio.
Watch next: Phase 1 safety/PK data readout; dose selection for Phase 2
Company milestone
CompletedActual: Oct 1, 2022
MSP-2020 selected as lead clinical candidate by Mindset Pharma (pre-acquisition)
Why it matters: MSP-2020 is a next-generation tryptamine/pyrrolidinylmethylindole with optimized pharmacology: greater potency than LSD combined with a shorter psychedelic duration than psilocybin. This profile could enable more practical clinical sessions.
Recorded Events
Oct 1, 2022: Company milestone
Evidence Links
Otsuka Pharmaceutical to Acquire Mindset Pharma
Press release - Otsuka Pharmaceutical - Sep 5, 2023 - Verified
Otsuka acquisition announcement confirms Mindset assets moved into Otsuka psychiatric and neurological pipeline.
Otsuka Pipeline - MSP-2020 Phase I
company-website - Otsuka Pharmaceutical - Mar 31, 2026 - Verified
Otsuka pipeline lists MSP-2020 as a Phase I oral programme related to psychiatry and neurology.
ClinicalTrials.gov NCT07329621 - MSP-2020 5-HT2A PET Binding Study
clinical-trial-registry - ClinicalTrials.gov - Jun 12, 2026 - Verified
Recruiting Phase 1 brain-imaging study assessing MSP-2020 binding to serotonin 5-HT2A receptors in healthy male adults.
Similar Developers
Reference points selected from shared pipeline stage, indications, compounds, regulatory pathways, and evidence footprint.
Apex Labs
Phase II2 active candidates1 trial
shared compound: Psilocybinsame indication: Major Depressive Disorder (MDD)Phase II peersimilar active pipeline size
Mydecine Innovations
Phase II2 active candidates
shared compound: PsilocybinPhase II peer2 shared regulatorssimilar active pipeline size
Ceruvia Lifesciences
Phase II2 active candidates2 trials
shared compound: PsilocybinPhase II peer2 overlapping stagessame regulator: US FDA
Quick Facts
- Type
- Public Biotech
- Ticker
- CSE: MSET
- Lead Stage
- Phase II
- Acquired by
- Otsuka Pharmaceutical
- Website
- Visit